Rheumnow Podcast

Panel discussion led by rheumatology experts Drs. Aurelie Najm, David Liew, and Jonathan Kay at EULAR 2024 meeting. Topics include disappointing trial results for bio-naive patients, challenges in treatment selection, importance of addressing depression, impact of medications on vaccination responses, debate on therapeutic drug monitoring in RA treatment, and use of innovative apps for remote patient monitoring in rheumatoid arthritis.

Rheumatology specialists Drs. Cush, Yusof, and Fava discuss cutting-edge lupus therapies at EULAR 2024 conference. Topics include steroid reduction strategies, B-cell targeting meds, and promising results of ionolumab for cell depletion. They delve into Lupus treatment trials, advances in lupus nephritis therapies, biomarkers for disease activity prediction, and the dynamic nature of lupus nephritis.

Moderated by Dr. Jack Cush and Featuring Drs. Eric Ruderman, Antoni Chan, and Peter Nash

Drs. Kavanaugh and Cush discuss topics from the EULAR 2024 Meeting, including the impact of anxiety on disease activity in RA patients, challenges in treating difficult cases of RA and psoriatic arthritis, recognizing and addressing depression symptoms, and exploring studies on ILD in RA patients. They also cover the use of AI in treatment analysis, CAR-T therapy for autoimmune diseases, and the efficacy of Dukravicitinib in managing lupus skin conditions.

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis? Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitor LB0005 Izokibep IL17A nanobody inhibitor POS0803 Vunakizumab, another IL17A inhibitor OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib Giant Cell Arteritis and Polymyalgia Rheumatica Update Dr. Janet Pope discusses abstracts LBA0001, OP0233, OP0261 and POS0280 at Eular 2024 in Vienna, Austria. JAK Inhibitors for New Indications Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria. Pain in RA: Different Drugs for Different Mechanisms Dr. Aurelie Najm reports from Eular 2024 in Vienna, Austria, about abstracts OP0072 and OP0086. Top 3 Messages About JAK Inhibitor Safety Dr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding JAKi safety. DMARDs and Herpes Zoster Vaccination: To Stop or Not To Stop Dr. Jonathan Kay discusses abstracts POS0620 and OP0020 presented at Eular 2024 in Vienna, Austria. Has JAK POT Hit the Spot About Infection Risk? Dr. Yuz Yusof discusses abstract OP0092 presented at Eular 2024 in Vienna, Austria. Select your GCA Therapy Dr. David Liew discusses LBA0001 presented at Eular 2024 in Vienna, Austria.  

Dr. Eric Ruderman discusses IL-17 and JAK Inhibitors in Spondyloarthritis and research abstracts presented at Eular 2024. Topics include MRI changes, telemonitoring effectiveness, radiomics predicting therapy outcomes, treating to target outcomes, early diagnosis of Axial Spondyloarthritis, and imaging in Axial Spondyloarthritis.

Does B Cell Depletion Matter? Drs. Yuz Yusof and Ed Vital discuss abstract OP0077 at Eular 2024 in Vienna, Austria. 3 Big Lupus Themes from EULAR 2024 Dr. Janet Pope discusses three hot topics in lupus at Eular 2024 in Vienna, Austria.  POS0732 OP0255 Voclosporin and Steroids in Lupus Nephritis Dr. Jack Cush reports on abstract OP0059 presented at Eular 2024 in Vienna, Austria. JAK Inhibitors for New Indications Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria. Cognitive Function in Older Adults with Lupus Dr. Mrinalini Dey discusses abstract POS0730 presented at Eular 2024 in Vienna, Austria. Does Withdrawing Steroids Increase Flares in SLE? Dr. Janet Pope reports on abstract OP0180 presented at Eular 2024 in Vienna, Austria. Tapering Treatment for Lupus Dr. Andrea Fava at Eular 2024 in Vienna, Austria, shares his perspectives on several sessions that addressed tapering treatment in lupus. The Crossroads of Autoinflammation and Autoimmunity Dr. Andrea Fava shares his perspectives on autoinflammation and autoimmunity at Eular 2024 in Vienna, Austria. We've Got to Talk about CAR T cells Dr. Yuz Yusof discusses abstract OP0017 presented at the Eular 2024 meeting in Vienna, Austria.    

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis? Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitor LB0005 Izokibep IL17A nanobody inhibitor POS0803 Vunakizumab, another IL17A inhibitor OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib JAK Inhibitors for New Indications Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria. PsA Treatment: is Earlier Better? Dr. Aurelie Najm discusses abstract OP0184, presented at Eular 2024 in Vienna, Austria. Transition from Psoriasis to PsA: Can we Prevent It? Dr. Aurelie Najm discusses abstract OP0010 presented at Eular 2024 in Vienna, Austria. Depression and Anxiety Associated with Inability to Achieve Remission in RA and PsA Dr. Aurelie Najm reports on abstract POS0946 presented at Eular 2024 in Vienna, Austria. PsA Switch or Cycle, the Eternal Question Dr. Aurelie Najm reports on abstracts POS0278 and POS0266 presented at Eular 2024 in Vienna, Austria. Axial & Psoriatic Disease Dr. Peter Nash at Eular 2024 in Vienna, Austria. Difficult to Treat Psoriatic Arthritis Dr. Peter Nash reports at Eular 2024 in Vienna, Austria. Predictors of Treatment Response in Psoriatic Arthritis Dr. Janet Pope reviews three abstracts presented at Eular 2024 in Vienna, Austria. Abstracts discussed:  POS 0990 POS 0992 POS 0266 Prevention of Psoriatic Arthritis Dr. Peter Nash sharing his perspectives on preventing psoriasis from turning into PsA at Eular 2024 in Vienna, Austria.  

Mechanistic Promise in RA Doesn’t Always Mean Actual Gain Dr. David Liew reports on abstracts OP0007 and OP0069 at Eular 2024 in Vienna, Austria. The Role of Psychosocial Determinants in the Management of Rheumatoid Arthritis Dr. Mrinalini Dey reports from Eular 2024 in Vienna, Austria about an abstract she will present during the meeting, POS0309. A Step Closer to Identifying Phenotypes of RA ILD Dr. Mrinalini Dey discusses abstract OP0202 presented at Eular 2024 in Vienna, Austria. Pain in RA: Different Drugs for Different Mechanisms Dr. Aurelie Najm reports from Eular 2024 in Vienna, Austria, about abstracts OP0072 and OP0086. Predicting Palindromic Prognosis Dr. David Liew discusses abstract OP0127 at Eular 2024 in Vienna, Austria. Top 3 Messages About JAK Inhibitor Safety Dr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding JAKi safety. Abatacept Misses on Shingrix Response Dr. David Liew discusses abstract POS0620 at Eular 2024 in Vienna, Austria. Artificial Intelligence Detection of CPPD on Hand Radiographs Dr. Antoni Chan interviews Dr. Thomas Hugle about abstract OP0112 presented at Eular 2024 in Vienna, Austria. Cognitive Function in Older Adults with Lupus Dr. Mrinalini Dey discusses abstract POS0730 presented at Eular 2024 in Vienna, Austria. Difficult-to-treat Rheumatoid Arthritis Validation of the EULAR Definition Dr. Mrinalini Dey discusses abstract OP0156 presented at Eular 2024 in Vienna, Austria. DMARDs and Herpes Zoster Vaccination To Stop or Not To Stop Dr. Jonathan Kay discusses abstracts POS0620 and OP0020 presented at Eular 2024 in Vienna, Austria. Has JAK POT Hit the Spot About Infection Risk? Dr. Yuz Yusof discusses abstract OP0092 presented at Eular 2024 in Vienna, Austria. Inspirations About RA-ILD Dr. Jonathan Kay discusses abstracts POS0070, POS0043 and POS0022 presented at the Eular 2024 meeting in Vienna, Austria. Depression and Anxiety Associated with Inability to Achieve Remission in RA and PsA Dr. Aurelie Najm reports on abstract POS0946 presented at Eular 2024 in Vienna, Austria. Digital Rheumatology Dr. Jonathan Kay reviews abstracts POS0451 and POS0607 presented at Eular 2024 in Vienna, Austria. Drug-resistant RA Does Blinatumomab BiTE? Dr. Yuz Yusof reports on abstract OP0193, presented at Eular 2024 in Vienna, Austria.  

Axial & Psoriatic Disease Dr. Peter Nash at Eular 2024 in Vienna, Austria. Difficult to Treat Psoriatic Arthritis Dr. Peter Nash reports at Eular 2024 in Vienna, Austria. Predictors of Treatment Response in Psoriatic Arthritis Dr. Janet Pope reviews three abstracts presented at Eular 2024 in Vienna, Austria. Abstracts discussed:  POS 0990 POS 0992 POS 0266 Prevention of Psoriatic Arthritis Dr. Peter Nash sharing his perspectives on preventing psoriasis from turning into PsA at Eular 2024 in Vienna, Austria. Depression and Anxiety Associated with Inability to Achieve Remission in RA and PsA Dr. Aurelie Najm reports on abstract POS0946 presented at Eular 2024 in Vienna, Austria. Digital Rheumatology Dr. Jonathan Kay reviews abstracts POS0451 and POS0607 presented at Eular 2024 in Vienna, Austria. Drug-resistant RA Does Blinatumomab BiTE? Dr. Yuz Yusof reports on abstract OP0193, presented at Eular 2024 in Vienna, Austria. Early Diagnosis of Axial Spondyloarthritis Dr. Antoni Chan reports on abstract OP0310 presented at Eular 2024 in Vienna, Austria. Imaging in Axial Spondyloarthritis Dr. Antoni Chan reviews abstracts OP0222 and OP0303 presented at Eular 2024 in Vienna, Austria.